• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Real Estate·000931.SZ
Share

Beijing Centergate Technologies Stocks

CN¥ 4.39Last Updated 16.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 472.37M

CN¥ 4.39
Key Takeaways

Risk factor

Good trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Beijing Centergate Technologies (holding) Co., Ltd. is a multifaceted corporation with a presence in both domestic Chinese and international markets. Its principal activities include the manufacturing and distribution of pharmaceuticals, undertaking construction projects, developing real estate, and providing property management services. The company's pharmaceutical division offers a diverse range of medicinal products, such as huasu west-ground iodine, fesser phenylcycline hydrochloride, bosu fuma acid bisolol, yuanji beni flat hydrochloric acid, and naloxone hydrochloride, along with various tablets and capsules like five plus biochemical and aramol quramado. In addition to traditional medicines, Beijing Centergate Technologies produces specialized oral and mucous membrane repair and health products, encompassing toothpaste, mouthwash, sprays, and dental equipment. These items are designed to address issues like ulcers, burns, mechanical damage, and support post-operative healing. Furthermore, the company supplies nutritional products and food-grade raw materials, including fruit enzymes, imported fungella enzymes, beneficial probiotics, and soda. Beyond its operational segments, the firm also allocates investments to high-tech sectors such as software, communications and electronic engineering, biomedicine, and other areas within the life sciences. Established in Beijing, China, in 1999, the company remains headquartered in its founding city.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBITDA, overval

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

16.07.2026 15:20

TSMC's profits hit a record high for the fifth consecutive quarter. Is the "AI megatrend" continuing?

16.07.2026 15:00

IPO Standard Nuclear: A developer of nuclear reactor fuel has gone public

16.07.2026 14:59

Csquare IPO: Shares of the data center provider are now available

16.07.2026 14:27

Shares of a small-cap psychedelic drug developer have soared. Eli Lilly may acquire the company.

16.07.2026 13:00

"Weeks, not months": The IEA warned of the threat of a global crisis over the Strait of Hormuz

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026